ISU Abxis Co. Ltd Total Liabilities

Latest as of September 2025: ₩45.29 Billion KRW ≈ $30.69 Million USD

ISU Abxis Co. Ltd total liabilities. Based on the latest financial reports, ISU Abxis Co. Ltd (086890) has total liabilities worth ₩45.29 Billion KRW (≈ $30.69 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ISU Abxis Co. Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of ISU Abxis Co. Ltd (2014–2024)

Total liabilities of ISU Abxis Co. Ltd from 2014 to 2024. This chart illustrates how ISU Abxis Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore ISU Abxis Co. Ltd (086890) investment intensity to see how much of total assets are deployed in long-term investments.

ISU Abxis Co. Ltd Competitors by Total Liabilities

The table below lists competitors of ISU Abxis Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Titanium Oyj
HE:TITAN
Finland €3.98 Million
Africa Energy Corp
V:AFE
Canada CA$316.00K
abrdn Asia Pacific Income Fund VCC
TO:FAP
Canada CA$45.34 Million
Clime Capital Ltd
AU:CAM
Australia AU$43.06 Million
Fine Blanking & Tool Co Ltd
TWO:4535
Taiwan NT$326.44 Million
Razor Labs Ltd
TA:RZR
Israel ILA54.66 Million
Gopeng Bhd
KLSE:2135
Malaysia RM244.71 Million
Sheetal Cool Products Limited
NSE:SCPL
India Rs1.08 Billion

Liability Composition Analysis (2014–2024)

This chart breaks down ISU Abxis Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ISU Abxis Co. Ltd total assets.

Liquidity & Leverage Metrics

ISU Abxis Co. Ltd Total Liabilities Ratios Explained

ISU Abxis Co. Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 2.05 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.38 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.27 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ISU Abxis Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ISU Abxis Co. Ltd (2014–2024)

The table below shows the annual total liabilities of ISU Abxis Co. Ltd from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 ₩59.37 Billion
≈ $40.23 Million
-54.17%
2023-12-31 ₩129.55 Billion
≈ $87.79 Million
+77.81%
2022-12-31 ₩72.86 Billion
≈ $49.38 Million
-7.94%
2021-12-31 ₩79.14 Billion
≈ $53.63 Million
+102.03%
2020-12-31 ₩39.17 Billion
≈ $26.55 Million
+4.24%
2019-12-31 ₩37.58 Billion
≈ $25.47 Million
+271.87%
2018-12-31 ₩10.11 Billion
≈ $6.85 Million
-35.69%
2017-12-31 ₩15.71 Billion
≈ $10.65 Million
+10.23%
2016-12-31 ₩14.26 Billion
≈ $9.66 Million
-39.11%
2015-12-31 ₩23.41 Billion
≈ $15.87 Million
-25.87%
2014-12-31 ₩31.59 Billion
≈ $21.41 Million
--

About ISU Abxis Co. Ltd

KQ:086890 Korea Pharmaceuticals
Market Cap
$62.34 Million
₩91.99 Billion KRW
Market Cap Rank
#20842 Global
#1178 in Korea
Share Price
₩3455.00
Change (1 day)
-2.68%
52-Week Range
₩2975.00 - ₩6240.00
All Time High
₩22450.00
About

ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long term enzyme repla… Read more